This review summarizes some representative AD-treatment small-molecule drugs that entered clinical trials mostly, alleviating the symptoms of AD through the development of cholinergic inhibitors, Aβ inhibitors, tau protein inhibitors, and other targeted drugs. Here, MAPT is linked to Alzheimer disease.